- Home
- ATAT vs FOLD Comparison
ATAT vs FOLD Comparison
Compare ATAT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- FOLD
- Stock Information
- Founded
- ATAT 2013
- FOLD 2002
- Country
- ATAT China
- FOLD United States
- Employees
- ATAT 4248
- FOLD N/A
- Industry
- ATAT Hotels/Resorts
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- FOLD Health Care
- Exchange
- ATAT Nasdaq
- FOLD Nasdaq
- Market Cap
- ATAT 3.6B
- FOLD 3.5B
- IPO Year
- ATAT 2022
- FOLD 2007
- Fundamental
- Price
- ATAT $26.00
- FOLD $9.68
- Analyst Decision
- ATAT Strong Buy
- FOLD Strong Buy
- Analyst Count
- ATAT 2
- FOLD 8
- Target Price
- ATAT $23.69
- FOLD $17.57
- AVG Volume (30 Days)
- ATAT 997.8K
- FOLD 2.6M
- Earning Date
- ATAT 11-19-2024
- FOLD 11-06-2024
- Dividend Yield
- ATAT 1.73%
- FOLD N/A
- EPS Growth
- ATAT 250.03
- FOLD N/A
- EPS
- ATAT 1.04
- FOLD N/A
- Revenue
- ATAT $834,559,715.00
- FOLD $493,671,000.00
- Revenue This Year
- ATAT $51.31
- FOLD $33.97
- Revenue Next Year
- ATAT $24.15
- FOLD $21.74
- P/E Ratio
- ATAT $25.11
- FOLD N/A
- Revenue Growth
- ATAT 91.74
- FOLD 32.58
- 52 Week Low
- ATAT $15.06
- FOLD $9.02
- 52 Week High
- ATAT $29.15
- FOLD $14.57
- Technical
- Relative Strength Index (RSI)
- ATAT 48.11
- FOLD 29.07
- Support Level
- ATAT $25.97
- FOLD $10.73
- Resistance Level
- ATAT $27.68
- FOLD $11.36
- Average True Range (ATR)
- ATAT 1.06
- FOLD 0.48
- MACD
- ATAT -0.20
- FOLD -0.20
- Stochastic Oscillator
- ATAT 41.07
- FOLD 1.49
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.